Ibandronic Acid Stada (Ibandronic Acid)

Ibandronic Acid binds to hydroxyapatite at sites of active bone turnover. When osteoclasts attach to this drug‑coated surface, the bisphosphonate is taken up into the cell, where it interferes with the mevalonate pathway, leading to osteoclast apoptosis and a consequent reduction in bone resorption.

The specific dose and infusion schedule of Ibandronic Acid Stada are determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Healthcare professionals should follow local prescribing guidelines and product labeling when selecting the appropriate regimen.

The safety of Ibandronic Acid Stada in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ibandronic Acid is a third‑generation bisphosphonate with a high affinity for bone mineral, allowing less frequent dosing (e.g., once‑monthly intravenous infusion) compared with some oral agents. Its potency in inhibiting osteoclasts is comparable to other IV bisphosphonates such as zoledronic acid, but individual patient factors and safety profiles guide the choice of therapy.

Ibandronic Acid Stada should be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and do not freeze or shake the vial. If the product must be transported, maintain the cold‑chain to preserve stability.

The medication is supplied as an intravenous solution and is administered by a qualified healthcare professional via a slow IV infusion. The infusion rate and duration are defined by the prescribing information and should be monitored for any acute‑phase reactions during administration.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe hypocalcaemia, acute renal impairment, and rare anaphylactic reactions. Patients should be monitored for signs of these conditions, and clinicians should assess risk factors before initiating therapy.

Ibandronic Acid Stada is contraindicated in patients with known hypersensitivity to ibandronate or any component of the formulation, in those with severe renal impairment (creatinine clearance <30 mL/min), and in individuals with untreated hypocalcaemia. Caution is also advised for pregnant or breastfeeding women unless clearly indicated.